Edwin M. Posadas, MD, FACP, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
More about this study > >